These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30598078)

  • 41. Integrated analysis of canine soft tissue sarcomas identifies recurrent mutations in TP53, KMT genes and PDGFB fusions.
    Das S; Idate R; Lana SE; Regan DP; Duval DL
    Sci Rep; 2023 Jun; 13(1):10422. PubMed ID: 37369741
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC.
    Kim Y; Lee B; Shim JH; Lee SH; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K
    J Thorac Oncol; 2019 Feb; 14(2):193-202. PubMed ID: 30391576
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines.
    Salawu A; Fernando M; Hughes D; Reed MW; Woll P; Greaves C; Day C; Alhajimohammed M; Sisley K
    Br J Cancer; 2016 Oct; 115(9):1058-1068. PubMed ID: 27560552
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
    Lowery CD; Blosser W; Dowless M; Knoche S; Stephens J; Li H; Surguladze D; Loizos N; Luffer-Atlas D; Oakley GJ; Guo Q; Iyer S; Rubin BP; Stancato L
    Clin Cancer Res; 2018 Feb; 24(4):847-857. PubMed ID: 29191969
    [No Abstract]   [Full Text] [Related]  

  • 45. Next-generation sequencing reveals mutations in RB1, CDK4 and TP53 that may promote chemo-resistance to palbociclib in ovarian cancer.
    El Shamieh S; Saleh F; Assaad S; Farhat F
    Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145688
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.
    Knudsen ES; Pruitt SC; Hershberger PA; Witkiewicz AK; Goodrich DW
    Trends Cancer; 2019 May; 5(5):308-324. PubMed ID: 31174843
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets.
    Cui Y; Han L; Shang J; Fang W; Zhao M; Chen D; Liu H
    Hum Pathol; 2022 May; 123():113-122. PubMed ID: 35181378
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Altered expression of G1 regulatory proteins in human soft tissue sarcomas.
    Yoo J; Park SY; Kang SJ; Shim SI; Kim BK
    Arch Pathol Lab Med; 2002 May; 126(5):567-73. PubMed ID: 11958662
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TP53 in bone and soft tissue sarcomas.
    Thoenen E; Curl A; Iwakuma T
    Pharmacol Ther; 2019 Oct; 202():149-164. PubMed ID: 31276706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma.
    Ohmoto A; Sato Y; Asaka R; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takeuchi K; Mori S; Takahashi S
    Mod Pathol; 2021 Nov; 34(11):1979-1989. PubMed ID: 34247193
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer.
    Liu JC; Granieri L; Shrestha M; Wang DY; Vorobieva I; Rubie EA; Jones R; Ju Y; Pellecchia G; Jiang Z; Palmerini CA; Ben-David Y; Egan SE; Woodgett JR; Bader GD; Datti A; Zacksenhaus E
    Cell Rep; 2018 Apr; 23(1):112-126. PubMed ID: 29617654
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts.
    Cornillie J; Wozniak A; Van Renterghem B; Van Winkel N; Wellens J; Gebreyohannes YK; Debiec-Rychter M; Sciot R; Hompes D; Schöffski P
    BMC Cancer; 2019 Jul; 19(1):724. PubMed ID: 31331295
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
    Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
    Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New therapeutic targets in soft tissue sarcoma.
    Demicco EG; Maki RG; Lev DC; Lazar AJ
    Adv Anat Pathol; 2012 May; 19(3):170-80. PubMed ID: 22498582
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma.
    Yee KS; Grochola L; Hamilton G; Grawenda A; Bond EE; Taubert H; Wurl P; Bond GL; O'Neill E
    Cancer Res; 2012 May; 72(9):2206-17. PubMed ID: 22389451
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human DNA damage checkpoints and their relevance to soft tissue sarcoma.
    Hattori H; Kuroda M; Ishida T; Shinmura K; Nagai S; Mukai K; Imakiire A
    Pathol Int; 2004 Jan; 54(1):26-31. PubMed ID: 14674991
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of adult soft tissue sarcoma: old concepts, new insights, and potential for drug discovery.
    Aragon-Ching JB; Maki RG
    Cancer Invest; 2012 May; 30(4):300-8. PubMed ID: 22480231
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?
    Riedel RF
    Semin Oncol; 2011 Oct; 38 Suppl 3():S30-42. PubMed ID: 22055970
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder.
    Liu F; Li Y; Ying D; Qiu S; He Y; Li M; Liu Y; Zhang Y; Zhu Q; Hu Y; Liu L; Li G; Pan W; Jin W; Mu J; Cao Y; Liu Y
    Signal Transduct Target Ther; 2021 Feb; 6(1):55. PubMed ID: 33563892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.